SCM
TSHA icon

Soleus Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Soleus Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-925,000
Closed -$2.65M – 111
2024
Q1 		$2.65M Buy
+925,000
New +$1.93M 0.2% 74

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Soleus Capital Management's TSHA Position: Q2 2024 in Review

Soleus Capital Management sold out of Taysha Gene Therapies (TSHA) in Q2 2024, closing a stake of 925,000 shares — an estimated $2.65M sold.

Soleus Capital Management first reported a position in TSHA in Q1 2024 and held it in 1 quarter. The position peaked at $2.65M in Q1 2024. 107 funds tracked by Wall St. Rank hold TSHA as of Q2 2024.

  • Soleus Capital Management reported no remaining Taysha Gene Therapies position as of Q2 2024 after selling out during the quarter.
  • Soleus Capital Management sold 925,000 Taysha Gene Therapies shares in Q2 2024, an estimated $2.65M.
  • Soleus Capital Management first reported a position in Taysha Gene Therapies in Q1 2024 and held it in 1 quarter.
  • Soleus Capital Management's Taysha Gene Therapies position peaked at $2.65M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2024.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.